Titlebook: Antidepressants; New Pharmacological Phil Skolnick Book 1997 Springer Science+Business Media New York 1997 calcium.lead.mood disorder.rese

Stable-Angina

Calcium Channel Antagonists in Mood Disorders,ressant, in 1956, numerous compounds have been developed and others have faded from the market. In fact, until the advent of the selective serotonin reuptake inhibitors (SSRIs) in the late 1980s, there had been no clear advances in the pharmacotherapy of mood disorders. Despite the fact that SSRIs o

使害羞

Functional NMDA Antagonists,rugs with no apparent structural relationship, but possessing similar clinical efficacies. Despite the similarity in therapeutic outcome, in vitro studies suggest that each class of antidepressant drugs predominantly modulates different neurotransmitters via either enzyme or reuptake inhibition. The

MOAN

Is an Adaptation of NMDA Receptors an Obligatory Step in Antidepressant Action?,(e g, imipramine and mianserin, respectively) to nonfused polyaromatic molecules (e.g., zimelidine) (Fig. 1). Most antidepressants have well-documented effects on either biogenic amine reuptake or metabolism, and it is these neurochemical properties (e.g., blockade of serotonin reuptake, inhibition

Anticoagulants

NMDA Receptors and Affective Disorders,7). Functional antagonists of the NMDA receptor complex, including a competitive NMDA antagonist (2-amino-7-phosphonoheptanoic acid [AP-7] ., a glycine partial agonist (1-aminocyclopropanecarboxylic acid [ACPC] ., and a use-dependent channel antagonist (dizocilpine ., are as efficacious as tricyclic

修饰语

积习已深

neuron

很是迷惑

Animal Models to Detect Antidepressants,rom the inadequacies of the therapies that are currently available. The traditional (first-generation) antidepressants suffer from three major drawbacks: They have unacceptable side effects; their efficacy is low; and their therapeutic effects develop slowly, typically requiring 3–4 wk of treatment

NIP

Molecular Strategies to Novel Antidepressant Discovery, one might legitimately ask, “Why do we need new antidepressant agents?” Indeed, the SSRIs and their less-selective predecessors, the tricyclic antidepressants and monoamine oxidase inhibitors, are effective in approx 65–70% of patients when systematically investigated in “double-blind” placebo-cont

Limited